Immunocore (NASDAQ:IMCR) Receives “Equal Weight” Rating from Morgan Stanley

Immunocore (NASDAQ:IMCR)‘s stock had its “equal weight” rating reiterated by equities research analysts at Morgan Stanley in a note issued to investors on Friday,Benzinga reports. They presently have a $35.00 target price on the stock. Morgan Stanley’s price target would suggest a potential upside of 17.45% from the stock’s current price.

IMCR has been the subject of several other research reports. HC Wainwright restated a “buy” rating and issued a $100.00 target price on shares of Immunocore in a research note on Friday, February 28th. Mizuho cut shares of Immunocore from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $72.00 to $38.00 in a research note on Monday, November 11th. Finally, Needham & Company LLC restated a “buy” rating and issued a $71.00 target price on shares of Immunocore in a research note on Thursday, February 27th. One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $65.64.

Immunocore Stock Down 3.3 %

IMCR stock opened at $29.80 on Friday. Immunocore has a one year low of $27.69 and a one year high of $66.00. The stock has a market capitalization of $1.49 billion, a PE ratio of -31.37 and a beta of 0.79. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. The company has a fifty day moving average of $30.16 and a 200-day moving average of $31.60.

Hedge Funds Weigh In On Immunocore

Hedge funds have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. purchased a new position in Immunocore during the 4th quarter valued at about $25,000. China Universal Asset Management Co. Ltd. increased its holdings in Immunocore by 12.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock valued at $248,000 after acquiring an additional 960 shares in the last quarter. NEOS Investment Management LLC grew its holdings in shares of Immunocore by 10.9% during the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock worth $330,000 after buying an additional 1,102 shares in the last quarter. Tema Etfs LLC purchased a new stake in shares of Immunocore during the fourth quarter worth about $330,000. Finally, Virtus ETF Advisers LLC grew its holdings in shares of Immunocore by 39.0% during the fourth quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company’s stock worth $340,000 after buying an additional 3,238 shares in the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.